Statement

  • Statement

    Incubate submits comment to CMS regarding its draft guidance for the Medicare Drug Price Negotiation Program
    04.17.2023

    Incubate submitted our feedback to the Centers for Medicare & Medicaid Services regarding its draft guidance for the Medicare Drug Price Negotiation Program.

  • Statement

    In Rejecting “March-In Rights” Petition for Xtandi, NIH Sends a Strong Message in Support of Intellectual Property Protections
    03.31.2023

    Earlier this week, the National Institutes of Health rejected a petition to initiate “march-in” proceedings.

  • Statement

    Incubate Testifies at USITC Hearing
    03.31.2023

    Executive Director John Stanford testified before the International Trade Organization.

  • Statement

    Life Science Venture Capital Responds to President Biden’s FY24 Budget 
    03.09.2023

    Today, March 9th, 2023, President Biden released his Fiscal Year (FY) 2024 proposed budget and recommendations. Notably, one proposal indicates that the President seeks to expand price controls established in the Inflation Reduction Act of 2022.

  • Statement

    Life Science Venture Capital Responds to President Biden’s State of the Union 
    02.08.2023

    We must bolster the scientific biopharmaceutical ecosystem, not abandon it. 

  • Statement

    Incubate Statement on Amendment 5284 of the Inflation Reduction Act
    08.06.2022

    Incubate issued the following statement in response to amendment 5284 of the Inflation Reduction Act:

  • Statement

    Incubate Letter on Reconciliation Drug Pricing Provisions
    07.15.2022

    Read Incubate's letter to the US Senate on their recent drug price provisions in the Reconciliation package

  • Statement

    Incubate Statement on Federal Drug Price Provisions
    07.06.2022

    See Incubate's statement in response to the recent Reconciliation bill text on drug price controls.

  • Statement

    Incubate Statement on WTO Decision to Suspend Global IP Rights
    06.30.2022

    The Incubate Coalition issued the following statement preceding the WTO TRIPS Council meeting (July 6-7) and following the World Trade Organization’s decision at its 12th Ministerial Conference in Geneva, Switzerland to waive intellectual property (IP) protections for Covid-19 vaccines.

  • Statement

    Incubate Comment in Response to the FTC’s Request for Comments on the Business Practices of PBMs
    05.25.2022

    Read Incubate's response to the FTC's Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers 

  • Statement

    Incubate Executive Director John Stanford Statement in Response to the Centers for Medicare & Medicaid Services’ Devastating Final National Coverage Determination for Certain Alzheimer’s Treatments
    04.14.2022

    See Executive Director John Stanford's statement on CMS' Final NCD on Alzheimer's disease and how this will affect the future of biopharmaceutical investment.